{
    "eid": "2-s2.0-85103589240",
    "title": "Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer",
    "cover-date": "2021-03-17",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "anticancer drug",
        "cancer stem cell",
        "drug repositioning",
        "lower toxicity",
        "MDR",
        "molecular targeting",
        "P-gp overexpresssion",
        "resistant cancer"
    ],
    "authors": [
        "Sungpil Yoon",
        "Xiaoju Wang",
        "Sompong Vongpunsawad",
        "Gerard Tromp",
        "Helena Kuivaniemi"
    ],
    "citedby-count": 9,
    "ref-count": 14,
    "ref-list": [
        "Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade",
        "New therapeutic bearings for repositioned drugs",
        "Metformin and ovarian cancer: the evidence",
        "Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review",
        "Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer",
        "Mechanisms of metformin inhibiting cancer invasion and migration",
        "Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells",
        "Low-dose crizotinib, a tyrosine kinase inhibitor, highly and specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro",
        "Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy",
        "Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer",
        "Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics",
        "Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance",
        "Perplexing role of P-glycoprotein in tumor microenvironment",
        "P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers"
    ],
    "affiliation": [
        {
            "affiliation-city": "Ann Arbor",
            "@id": "60033182",
            "affilname": "University of Michigan Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033182",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60007511",
            "affilname": "Sungkyunkwan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007511",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Stellenbosch",
            "@id": "60001565",
            "affilname": "Stellenbosch University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001565",
            "affiliation-country": "South Africa"
        }
    ],
    "funding": [
        "Faculty of Medicine and Health Sciences",
        "Ministry of Education",
        "National Research Foundation of Korea",
        "Stellenbosch University"
    ]
}